Testicular germ cell cancer (TGCC) is rare form of malignant disease that occurs mostly in young man between age 15 and 40. The worldwide incidence of TGCC is 1.5 per 100000 man with the highest rates in North Europe. After discovery of cisplatin cure rates of TGCC are very favorable between 90%-95% and unlike most solid tumors, cure rate for metastatic TGCC is around 80%. Metastatic TGCC is usually treated with 3-4 cycles of bleomycin, etoposide, cisplatinum chemotherapy with or without retroperitoneal surgery and cure rates with this approach are between 41% in poor risk group and 92% in good risk group of patients. Cure rates are lower in relapsed and refractory patients and many of them will die from the disease if not cured with first line chemotherapy. High dose chemotherapy (HDCT) approach was used for the first time during the 1980s. Progress in hematology allowed the possibility to keep autologous haematopoietic stem cells alive ex-vivo at very low temperatures and use them to repopulate the bone marrow after sub-lethal dose of intesive myeloablative chemotherapy. Despite the fact that there is no positive randomized study to prove HDCT concept, cure rates in relapsed TGCC are higher after high dose therapy then in historical controls in studies with conventional treatment. Here we review clinical studies in HDCT for TGCC, possibilities of mobilising sufficient number of stem cells and future directions in the treatment of this disease.

中文翻译：

---

干细胞支持的大剂量化学疗法可治疗睾丸癌。

睾丸生殖细胞癌（TGCC）是一种罕见的恶性疾病，主要发生在15岁至40岁之间的年轻人中。全球TGCC的发病率是每100000人中有1.5例，在北欧发病率最高。发现顺铂的TGCC治愈率在90％-95％之间非常有利，并且与大多数实体瘤不同，转移性TGCC的治愈率约为80％。转移性TGCC通常用3-4个周期的博来霉素，依托泊苷，顺铂化疗进行或不进行腹膜后手术，这种方法的治愈率在低风险组的患者中为41％，在高风险组的患者中为92％。复发和难治性患者的治愈率较低，如果不通过一线化疗治愈，其中许多人将死于疾病。在1980年代首次使用高剂量化疗（HDCT）方法。血液学方面的进展使得在低温下进行致命的清髓性化学疗法后，自体造血干细胞能够在极低的温度下保持体外存活，并利用它们重新填充骨髓。尽管尚无阳性随机研究证明HDCT概念，但高剂量治疗后复发性TGCC的治愈率高于传统治疗研究中的历史对照。在这里，我们回顾了HDCT中TGCC的临床研究，动员足够数量的干细胞的可能性以及治疗该疾病的未来方向。尽管尚无阳性随机研究证明HDCT概念，但高剂量治疗后复发性TGCC的治愈率高于传统治疗研究中的历史对照。在这里，我们回顾了HDCT中TGCC的临床研究，动员足够数量的干细胞的可能性以及治疗该疾病的未来方向。尽管尚无阳性随机研究证明HDCT概念，但高剂量治疗后复发性TGCC的治愈率高于传统治疗研究中的历史对照。在这里，我们回顾了HDCT中TGCC的临床研究，动员足够数量的干细胞的可能性以及治疗该疾病的未来方向。